Rosenberg's Molecular and Genetic Basis of Neurological and Psychiatric Disease, Seventh Edition

Volume 1

7th Edition, Volume 1 - September 27, 2024
Imprint: Academic Press
Editors: Roger N. Rosenberg, Juan M. Pascual
Language: English
Hardback ISBN:
9 7 8 - 0 - 4 4 3 - 1 9 0 4 1 - 4
eBook ISBN:
9 7 8 - 0 - 4 4 3 - 1 9 0 4 2 - 1

Rosenberg’s Molecular and Genetic Basis of Neurologic and Psychiatric Disease, Seventh Edition, provides a comprehensive introduction and reference to the foundations and key pr… Read more

Purchase options

BLOOM INTO SPRING SAVINGS

Save up to 25% on books and eBooks!

Shop now

Institutional subscription on ScienceDirect

Request a sales quote

Rosenberg’s Molecular and Genetic Basis of Neurologic and Psychiatric Disease, Seventh Edition, provides a comprehensive introduction and reference to the foundations and key practical aspects relevant to neurologic and psychiatric disease. This volume has been thoroughly revised and includes newly commissioned chapters on ethics, genetic counselling and genet therapy for the central nervous system disorders. A favorite of over four generations of students, clinicians and scholars, this new edition retains and expands the informative, concise and critical tone of the previous edition. This is an essential reference for general medical practitioners, neurologists, psychiatrists, geneticists, and related professionals, and for the neuroscience and neurology research community at large.

SECTION I. GENERAL CONCEPTS AND TOOLS

1. Mendelian, non-mendelian, multigenic inheritance and epigenetics

2. Precision medicine in neurology

3. Epigenomics of neurological disorders

4. What genes can and cannot do

5. Genotype-phenotype considerations in neurogenetic disease

6. Immunogenetics of neurological disease

7. Pharmacogenomic approaches to the treatment of sporadic alzheimer's disease

8. Application of mouse genetics to human disease: Generation and analysis of mouse models

9. DNA sequencing and other methods of exonic and genomic analyses

10. Association, cause and causal association. Revision 2: Playing the changes.

11. Adeno-associated virus-mediated gene therapy in central nervous system genetic disorders

12. Genomics of human neurological disorders

13. CRISPR/Cas9-based genetic engineering for translational research in neurological disorders

14. Neural cells derived from pluripotent stem cells and directly induced from somatic cells

15. Neuroimaging in dementia

16. Neuroethics

17. Genetic counseling

18. Antisense oligonucleotide drugs for neurological and neuromuscular diseases

19. Autophagy and neurological disorders

20. The aging brain

SECTION II. NEUROLOGIC DISEASES

21. Cerebral malformations

22. Global developmental delay and intellectual disability

23. Aging and dementia in down syndrome

24. An overview of rett syndrome

25. Fragile X clinical features and neurobiology

26. Neurological evaluation and management of autism spectrum disorder

27. Angelman syndrome

28. The prion diseases

29. Leptin-related disorders of the nervous system

30. Genetics of autonomic disorders

SECTION III. NEUROMETABOLIC DISORDERS

Mitochondrial Disorders

31. The mitochondrial genome

32. Mitochondrial disorders due to mutations in the mitochondrial genome

33. Mitochondrial disorders due to mutations in the nuclear genome

34. Pyruvate dehydrogenase, pyruvate carboxylase, krebs cycle and mitochondrial transport disorders

Lysosomal Disorders

35. Gaucher disease – neuronopathic forms

36. The Niemann-Pick diseases

37. GM2-gangliosidoses

38. Metachromatic leukodystrophy and multiple sulfatase deficiency

39. Krabbe disease: Globoid cell leukodystrophy

40. Leukodystrophies--an overview

41. The mucopolysaccharidoses

42. The mucolipidoses

43. Disorders of glycoprotein degradation: α-mannosidosis, β-mannosidosis, fucosidosis, sialidosis, and aspartylglycosaminuria

44. GM1 gangliosidosis, Morquio Disease, galactosialidosis and sialidosis

45. Acid ceramidase deficiency: Farber lipogranulomatosis, spinal muscular atrophy associated with progressive myoclonic epilepsy and peripheral osteolysis

46. Wolman disease

47. Lysosomal membrane disorders: lysosome-associated membrane protein-2 deficiency (Danon disease)

48. Fabry disease: α-galactosidase A deficiency

49. Schindler disease: deficient α -N-acetylgalactosaminidase activity

SECTION IV: METABOLIC DISORDERS

50. Organic acid disorders

51. Glycogen and polyglucosan storage diseases

52. Disorders of galactose metabolism

53. Inborn Errors of Amino Acid Metabolism

54. Urea cycle disorders

55. Glucose transporter type I deficiency and other glucose flux disorders

56. Maple syrup urine disease: biochemical, clinical and therapeutic considerations

57. Congenital disorders of N-linked glycosylation

58. Disorders of glutathione metabolism

59. Canavan disease

60. Neurotransmitter disorders

61. Peroxisomal disorders

62. Purines and pyrimidines

63. The acute porphyrias

Roger N. Rosenberg

Roger N. Rosenberg, MD is a graduate of Northwestern University Medical School, With Distinction, and was subsequently trained in Neurology with H. Houston Merritt, MD at the Neurological Institute, Columbia University, New York, was Chief Resident and then was a Post-Doctoral Fellow with Nobel Laureate Marshall Nirenberg at the NIH in the Laboratory of Biochemical Genetics. He is Board Certified by the American Board of Psychiatry and Neurology. He is holder of the Zale Distinguished Chair and Professor of Neurology and Neurotherapeutics at the University of Texas Southwestern Medical Center at Dallas since 1973 and developed the department for 18 years as Chair from 1973-1991. He described for the first time in 1975 Machado Joseph disease, an autosomal dominant cerebellar degeneration, which produces imbalance and impaired coordination, and showed it was due to a unique expansion of DNA in the causal gene. It is the most common inherited form of impaired coordination in the world and his research has provided a genetic marker to eliminate it in large families in future generations. He has served as the Founding Director of the UT Southwestern NIH funded Alzheimer’s Disease Center and Principal Investigator of the NIH Center Grant from 1987-2019. He directs an active laboratory effort in Alzheimer’s Disease. He is developing a DNA Aβ42 trimer vaccine for Alzheimer's disease for which he was awarded a US Patent "Amyloid Beta Gene Vaccines" in January 2009. It has been tested in mouse, transgenic mouse, New Zealand white rabbits and rhesus monkeys. The vaccine produces effective anti-Aβ42 peptide antibody levels and is non-inflammatory in all three species. The vaccine reduces by 40% Aβ42 peptide and by 50% tau and phospho-tau in the brains of 3X AD Tg mice, the two main pathologies of Alzheimer’s disease, with high levels of anti-Aβ42 antibody and with a non-inflammatory immune response. He is preparing now a Phase 1 Clinical trial Grant - First in Human to determine its effectiveness and safety in human subjects. He has published 297 original scientific articles, chapters, reviews, and editorials. He served as Editor in Chief from 1997 through 2017 for JAMA Neurology (formerly Archives of Neurology), a major international neurology journal, published by the American Medical Association. During his tenure, he raised the Impact Factor of the journal from 3.0 to 10.2, placing JAMA Neurology as #1 of all US publications in neurology. He is the founding editor of two of the landmark texts in neuroscience. Rosenberg’s Molecular and Genetic Basis of Neurological and Psychiatric Disease, 5th edition, published in 2015 by Elsevier. The 6th edition will publish in 2020. The Atlas of Clinical Neurology, 4th edition, has just been published. He is a former President of the American Academy of Neurology, former Vice-President of the American Neurological Association, an Honorary Member of both organizations, and a Fellow of the American Association for the Advancement of Science. He received the first Science Medal in 2009 from the World Federation of Neurology for his contributions to neuro-genetics, for his original clinical and molecular genetics research on Machado-Joseph disease, and the development of the DNA Abeta42 trimer vaccine for Alzheimer’s disease.

Affiliations and expertise

Abe (Brunky), Morris and William Zale Distinguished Chair in Neurology, Professor of Neurology and Neurotherapeutics, Founding Director, Alzheimer’s Disease Center Head, Section on Memory and Behavioral Neurology, University of Texas Southwestern Medical Center, Dallas, Texas, USA

Juan M. Pascual

Juan M. Pascual, M.D., Ph.D., is the inaugural holder of The Once Upon a Time Foundation Professorship in Pediatric Neurologic Diseases and also holds the Ed and Sue Rose Distinguished Professorship in Neurology. His laboratory research interests span virtually the entire field of neuroscience, including medical neuroscience, from molecular structure and function (including drug action), neural physiology and metabolism at the cellular, circuit and whole-brain level and neurogenetics, all of which is complemented with neurological patient care and clinical trials. Laboratory research greatly influences his clinical activities and patient observations guide his laboratory research direction. As a clinician, Dr. Pascual specializes in genetic and metabolic diseases of the nervous and neuromuscular systems of infants, children, and adults with a particular emphasis on complex diagnostic problems, second opinions for patients visiting from the rest of the U.S. and abroad, and in clinical trials. Dr. Pascual has special clinical research expertise in undiagnosed and rare diseases, glucose metabolism, mitochondrial, degenerative, and multi-organ disorders. Dr. Pascual is a tenured faculty member in four Departments at UT Southwestern Medical Center: Neurology and Neurotherapeutics, Physiology, Pediatrics, and the Eugene McDermott Center for Human Growth & Development / Center for Human Genetics. He is also Director of the Rare Brain Disorders Program (Clinic and Laboratory). He is also a member of the Division of Pediatric Neurology, of the graduate Ph.D. programs in Neuroscience and Integrative Biology, and of the postgraduate clinical training programs in Neurology, Pediatric Neurology, Pediatrics, and Medical Genetics. He teaches at UT Southwestern Medical School. In addition, Dr. Pascual is an adjunct professor in the Department of Biological Sciences at the School of Natural Sciences and Mathematics, The University of Texas at Dallas. Dr. Pascual directs a highly collaborative research laboratory and is credentialed campus-wide at Children's Medical Center Dallas, UT Southwestern University Hospitals and Clinics, and Parkland Memorial Hospital, where he consults on inpatients and outpatients with particularly complex or severe diseases. Much of his research is funded by the National Institutes of Health. Dr. Pascual received his M.D. degree with unique distinction from the Universidad de Granada, Spain, one of the oldest universities in the world, founded in 1349 by Yusuf I, Sultan of Granada and one of the builders of the Alhambra. He received his Ph.D. degree in Molecular Physiology and Biophysics from Baylor College of Medicine in Houston, Texas, under Arthur M. Brown, M.D., Ph.D., McCollum Professor and Chair. His postdoctoral research was conducted under Arthur Karlin, Ph.D., Higgins Professor and Director of the Center for Molecular Recognition, College of Physicians and Surgeons of Columbia University and, later, at the Colleen Giblin Research Laboratories for Pediatric Neurology at the same institution under a Neurological Sciences Academic Development Award from the National Institute of Neurological Disorders and Stroke. He also received residency training in Pediatrics at Washington University School of Medicine - St. Louis Children's Hospital and in Neurology and Pediatric Neurology at the Neurological Institute of New York - Columbia University Medical Center. He received certification in Neurology with Special Qualification in Child Neurology from the American Board of Psychiatry and Neurology.

Affiliations and expertise

Dept Neurology and Neurotherapeutics, Physiology and Pediatrics; McDermott Ctr for Human Growth and Dev/Ctr for Human Genetics, Univ of Texas Southwestern Medical Ctr, Dallas, TX, USA

Life Sciences

Physical Sciences & Engineering

Social Sciences & Humanities

Health